Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

Oncotarget

Volumn 6, Issue 20, 2015, Pages 18192-18205

  Podrazil, Michal ^a   Horvath, Rudolf ^a   Becht, Etienne ^c,d,e   Rozkova, Daniela ^b   Bilkova, Pavla ^b   Sochorova, Klara ^a,b   Hromadkova, Hana ^a   Kayserova, Jana ^a   Vavrova, Katerina ^a   Lastovicka, Jan ^a   Vrabcova, Petra ^a   Kubackova, Katerina ^a   Gasova, Zdenka ^f   Jarolim, Ladislav ^a   Babjuk, Marek ^a   Spisek, Radek ^a,b   Bartunkova, Jirina ^a,b   Fucikova, Jitka ^a,b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Sotio   (Czech Republic)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Castration resistant prostate cancer; Dendritic cell; Immunotherapy; Overall survival; Prostate cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; IMIQUIMOD; PREDNISONE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHOROID MELANOMA; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPRESSION FRACTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HEART INFARCTION; HEMIPARESIS; HUMAN; HYDRONEPHROSIS; HYPOKALEMIA; HYPOTENSION; IMMUNOGLOBULIN DEFICIENCY; INCONTINENCE; JAW OSTEONECROSIS; KIDNEY FAILURE; LEUKAPHERESIS; LEUKOPENIA; LUNG EDEMA; LUNG EMBOLISM; MALE; MENINGIOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NOMOGRAM; OPEN STUDY; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PARAPLEGIA; PATHOLOGIC FRACTURE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REGULATORY T LYMPHOCYTE; SHOCK; THROMBOCYTOPENIA; THROMBOSIS; TOXIC MYOPATHY; TREATMENT RESPONSE; URINARY TRACT INFLAMMATION; URINARY TRACT OBSTRUCTION; URINE RETENTION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CLINICAL TRIAL; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; SECONDARY; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADENOCARCINOMA; ADMINISTRATION, METRONOMIC; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NOMOGRAMS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; T-LYMPHOCYTE SUBSETS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938586430     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4145     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008; 112:1247-1253.
3. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: efficacy and safety. European urology. 2011; 60:279-290.
4. Maluf FC, Smaletz O, Herchenhorn D. Castration-resistant prostate cancer: systemic therapy in 2012. Clinics. 2012; 67:389-394.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004; 351:1513-1520.
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:242-245.
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012; 367:1187-1197.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011; 364:1995-2005.
9. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer management and research. 2013; 5:1-14.
10. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature reviews Cancer. 2002; 2:389-396.
11. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014; 5:12472-12508.
12. Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer immunology, immunotherapy : CII. 2013; 62:137-147.
13. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nature reviews Drug discovery. 2011; 10:591-600.
14. Butterfield LH. Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress? Frontiers in immunology. 2013; 4:454.
15. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nature reviews Cancer. 2006; 6:24-37.
16. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21:137-148.
17. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nature reviews Drug discovery. 2012; 11:215-233.
18. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International journal of cancer. 2013; 133:624-636.
19. Carson WE 3rd, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:3401-3409.
20. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16:4583-4594.
21. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Frontiers in bioscience: a journal and virtual library. 2007; 12:4957-4971.
22. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005; 105:2862-2868.
23. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer research. 2003; 63:8408-8413.
24. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type Iinterferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000; 95:2024-2030.
25. Rozkova D, Tiserova H, Fucikova J, Last'ovicka J, Podrazil M, Ulcova H, Budinsky V, Prausova J, Linke Z, Minarik I, Sediva A, Spisek R, Bartunkova J. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical immunology. 2009; 131:1-10.
26. Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartunkova J, Spisek R. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. Journal of translational medicine. 2011; 9:223.
27. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, Rob L, Bartunkova J, Spisek R. High hydrostatic pressure induces immunogenic cell death in human tumor cells. International journal of cancer. 2014; 135:1165-1177.
28. Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, Fucikova J, Kocian P, Rob L, Bartunkova J, Spisek R. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. International journal of cancer. 2013; 132:1070-1079.
29. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21:1232-1237.
30. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20:3972-3982.
31. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nature reviews Immunology. 2010; 10:580-593.
32. Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013; 2:e25771.
33. Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. International journal of cancer. 2007; 121:467-473.
34. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450:903-907.
35. Spisek R. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer. Expert Rev Anticancer Ther. 2006; 6:1689-1691.
36. Spisek R, Dhodapkar MV. Immunoprevention of cancer. Hematology/oncology clinics of North America. 2006; 20:735-750.
37. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annual review of immunology. 2013; 31:51-72.
38. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature medicine. 2007; 13:54-61.
39. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spisek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer research. 2011; 71:4821-4833.
40. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007; 109:4839-4845.
41. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. The New England journal of medicine. 2007; 357:2696-2705.
42. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer immunology, immunotherapy: CII. 2009; 58:823-830.
43. Nouri-Shirazi M, Banchereau J, Fay J, Palucka K. Dendritic cell based tumor vaccines. Immunol Lett. 2000; 74:5-10.
44. Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus post-vaccination. Cancer immunology, immunotherapy: CII. 2011; 60:197-206.
45. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer metastasis reviews. 2014; 33:641-655.